A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan

BMS-986012 in Relapsed/Refractory SCLC

NCT02247349 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer

NCT02613507 ·Status: COMPLETED ·Phase: PHASE3

An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

NCT02477826 ·Status: COMPLETED ·Phase: PHASE3

A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer

NCT02967133 ·Status: TERMINATED ·Phase: PHASE2

A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC

NCT07141563 ·Status: COMPLETED

A Study of NK012 in Patients With Relapsed Small Cell Lung Cancer

NCT00951613 ·Status: COMPLETED ·Phase: PHASE2

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

NCT02041533 ·Status: COMPLETED ·Phase: PHASE3

An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

NCT02869789 ·Status: COMPLETED ·Phase: PHASE4

Study of S-588410 After Adjuvant Chemotherapy for Completely Resected Non-small- Cell Lung Cancer

NCT02410369 ·Status: UNKNOWN ·Phase: PHASE2

Real Life Second-Line Nivolumab in Advanced Non-Small Cell Lung Cancer

NCT04858204 ·Status: COMPLETED

A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan (NEOREAL)

NCT07169708 ·Status: RECRUITING

Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer

NCT04211896 ·Status: UNKNOWN ·Phase: PHASE2

A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China

NCT04015778 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer

NCT03048136 ·Status: WITHDRAWN ·Phase: PHASE3

A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC

NCT03215706 ·Status: COMPLETED ·Phase: PHASE3

Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.

NCT03262779 ·Status: COMPLETED ·Phase: PHASE2

Gemcitabine and Carboplatin for Elderly Patient With Lung Cancer

NCT00881296 ·Status: COMPLETED ·Phase: PHASE2

Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer

NCT03091491 ·Status: TERMINATED ·Phase: PHASE2

Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform

NCT03692442 ·Status: UNKNOWN

Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC

NCT02259621 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer

NCT03121417 ·Status: WITHDRAWN ·Phase: PHASE2

Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy

NCT06667154 ·Status: RECRUITING ·Phase: PHASE2

An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

NCT03417037 ·Status: WITHDRAWN ·Phase: PHASE3

Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice

NCT02847728 ·Status: COMPLETED

Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen

NCT02475382 ·Status: NO_LONGER_AVAILABLE